Compounded Tirzepatide Vial Math: From Vial Label to Syringe to Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Compounded tirzepatide is dispensed as multi-dose vials labeled with total milligrams, total volume, and concentration in mg/mL.
• The number of doses per vial depends on vial size and prescribed dose; common configurations deliver 4 to 20 doses.
• The vial concentration on the pharmacy label is the single most important number for any dose calculation.
• Volume in mL for any dose equals dose in mg divided by concentration in mg/mL.
• Beyond-use dates set by the compounding pharmacy define how long the vial can be used after first puncture.

Direct answer

Compounded tirzepatide vial math hinges on three numbers from the pharmacy label: total milligrams in the vial, total volume in milliliters, and concentration in mg/mL. The volume for any prescribed dose equals dose in mg divided by concentration in mg/mL, and the corresponding units on a U-100 insulin syringe equals volume in mL multiplied by 100. The vial label, not a generic calculator, is the source of truth for the specific vial in front of the patient.

Table of contents

1. What's on a compounded tirzepatide vial label
2. The three numbers that matter
3. The dose-to-volume formula
4. Common compounded vial configurations
5. How many doses come out of a vial
6. The pharmacy's beyond-use date
7. The syringe choice: 0.3, 0.5, or 1 mL
8. Drawing technique and dose accuracy
9. Why the math fails: common errors
10. The contrary view on vial vs pen
11. Decision framework
12. FAQ
13. Sources

What's on a compounded tirzepatide vial label

A pharmacy-prepared tirzepatide vial label typically includes:

• Patient name
• Drug name (Tirzepatide or "compounded tirzepatide")
• Strength: concentration in mg/mL, total milligrams in vial, total volume in mL
• Lot number and beyond-use date
• Storage instructions
• Pharmacy name, NPI, and contact information
• Prescriber name and date prescribed
• Sig (directions for use), including the patient's prescribed dose

The "Sig" line is the prescribing clinician's instruction. It usually states the prescribed milligram dose, the injection frequency, and any titration notes. This is the source of truth for the patient's dose, not generic dose tables.

The three numbers that matter

Vial math reduces to three quantities.

Number	What it is	Where to find it
Total milligrams	Total tirzepatide in the vial	Pharmacy label: "Total: X mg"
Total volume	Total liquid in the vial	Pharmacy label: "Volume: X mL"
Concentration	Milligrams per milliliter	Pharmacy label: "X mg/mL" or calculated from above

If the label states "50 mg/5 mL" the concentration is 10 mg/mL. If it states "60 mg/3 mL" the concentration is 20 mg/mL. Always read directly from the label rather than relying on memory or a prior vial.

The dose-to-volume formula

Once concentration is known, the volume for any dose is straightforward:

• Volume in mL = dose in mg / concentration in mg/mL
• Units on a U-100 syringe = volume in mL x 100

Worked examples for common doses on a 10 mg/mL vial:

Dose (mg)	Volume (mL)	Units on U-100 syringe
2.5	0.25	25
5.0	0.50	50
7.5	0.75	75
10.0	1.00	100
12.5	1.25	125
15.0	1.50	150

For volumes above 100 units (1.0 mL), a 1 mL syringe is not enough and the patient must use a larger syringe or split the dose. Most pharmacies preparing 10 mg/mL vials for higher doses include a 1 mL syringe and explicit drawing instructions to handle the volume.

Common compounded vial configurations

Compounded tirzepatide vials in the U.S. typically come in a handful of standard configurations. Pharmacies select the configuration based on the patient's titration schedule and how long the prescription is intended to last.

Vial total	Volume	Concentration	Typical use
20 mg	2 mL	10 mg/mL	Starting doses, 8-week supply at 2.5 mg
50 mg	5 mL	10 mg/mL	20 doses at 2.5 mg, 10 doses at 5 mg
60 mg	3 mL	20 mg/mL	Mid-titration doses, smaller injection volumes
90 mg	3 mL	30 mg/mL	Higher doses (7.5-15 mg), reduced injection volume
120 mg	3 mL	40 mg/mL	Maximum dose use, smallest injection volumes

Higher concentrations are convenient for high-dose patients but require careful measurement because small volume changes produce large dose changes.

How many doses come out of a vial

Dividing total milligrams by prescribed dose gives the number of doses available, before accounting for residual volume that cannot be drawn.

Vial size	Prescribed dose	Doses available (label)	Useful doses (practical)
50 mg / 5 mL / 10 mg/mL	2.5 mg	20	18-19 (residual loss)
50 mg / 5 mL / 10 mg/mL	5 mg	10	9-10
50 mg / 5 mL / 10 mg/mL	7.5 mg	~6.7	6 (rounding down)
60 mg / 3 mL / 20 mg/mL	5 mg	12	11-12
120 mg / 3 mL / 40 mg/mL	15 mg	8	7-8

"Practical" doses are typically one less than the label maximum because the last 0.05-0.10 mL of vial volume is hard to draw cleanly. Pharmacies usually account for this when they decide how many weeks of therapy to dispense per vial.

The pharmacy's beyond-use date

Compounded sterile preparations have a beyond-use date set by the compounding pharmacy. The beyond-use date is the last day the medication can be used per USP 797 standards and the pharmacy's stability data.

Common compounded tirzepatide beyond-use dates range from 28 to 90 days from the date the vial was prepared. Some pharmacies use shorter dates for conservative practice; others use longer dates supported by stability testing.

The beyond-use date is the controlling number for vial longevity. Even if the vial has unused medication after the beyond-use date, the medication should not be used. Compounded preparations do not have the same multi-year stability data that FDA-approved manufacturers have for their products.

The syringe choice: 0.3, 0.5, or 1 mL

The right syringe depends on the dose volume:

Dose volume	Recommended syringe	Reason
Up to 0.30 mL (30 units)	0.3 mL U-100	Finest markings, best accuracy at low volumes
0.30 to 0.50 mL	0.5 mL U-100	Reasonable accuracy, larger volume range
0.50 to 1.0 mL	1 mL U-100	Volume capacity, with somewhat coarser markings
Above 1.0 mL	Larger syringe or split dose	Single U-100 syringe cannot hold the volume

Pharmacies typically include the right syringe with the prescription. Patients who run out of the included syringes should not improvise with non-U-100 syringes, which use different markings and can cause dose errors.

Drawing technique and dose accuracy

Pharmacy-instructional drawing technique covers:

1. Wash hands and prepare a clean work surface.
2. Inspect the vial: clear, colorless, no particulates, within the beyond-use date.
3. Wipe the vial stopper with an alcohol swab.
4. Pull back on the syringe plunger to draw air equal to the desired dose volume.
5. Insert the needle through the stopper, push the air in (this prevents vacuum).
6. Invert the vial, draw the medication slowly, drawing slightly more than needed.
7. Tap the syringe to dislodge air bubbles, push back any excess medication until the volume marking matches the prescribed dose.
8. Remove the needle from the vial, recap if using a separate injection needle.

Drawing slightly more than needed and pushing back to the exact volume is the standard pharmacy technique for accuracy. It also clears air from the syringe.

Why the math fails: common errors

FDA adverse-event reports and 503A pharmacy quality reviews highlight recurring sources of compounded-tirzepatide dose errors.

Error 1: assuming the concentration from a prior fill. Pharmacies change formulations; a 10 mg/mL vial may be replaced with a 20 mg/mL vial on the next refill. Patients who don't recheck the concentration and continue using the old volume deliver double the dose.

Error 2: confusing units with milligrams. A patient who hears "ten" and draws ten units instead of the correct volume can be off by a factor of 10.

Error 3: drawing air. Visible air bubbles in the syringe reduce the actual medication volume delivered.

Error 4: using a non-insulin syringe. Tuberculin or other syringe types use different markings; a 1 mL line on a tuberculin syringe is not equivalent to 100 units on a U-100 syringe.

Error 5: ignoring the beyond-use date. Stretched vials beyond their beyond-use date have unverified potency and sterility.

The contrary view on vial vs pen

The case for vials: lower per-dose cost, smaller refrigerator footprint, flexibility to dose at any titration step without a new pen format. For patients comfortable with sterile technique and dose math, vials offer real advantages.

The case against vials: more patient-side error opportunities, less convenient than auto-injectors, requires sterile technique and dose calculation skills that not all patients have, and dispensed without the safety features of an FDA-approved auto-injector.

The current U.S. market reflects this trade-off: compounded vials grew rapidly during the 2022-2024 tirzepatide shortage and have remained an option even as supply has stabilized. Patients who prefer the pen format for ease of use are still likely to choose Mounjaro or Zepbound; patients who prioritize cost lean toward compounded vials.

Decision framework

If you are starting compounded tirzepatide:

• Read the vial label carefully. Note the concentration in mg/mL.
• Calculate the volume for your prescribed dose using volume = dose / concentration.
• Confirm against your prescriber's written instructions before injecting.

If you are refilling and the concentration changed:

• Recalculate the volume. The previous syringe reading is no longer correct.
• Verify with the pharmacy if anything looks off.

If you are uncomfortable with sterile technique or dose math:

• Consider switching to an FDA-approved pen (Mounjaro for diabetes, Zepbound for weight management).
• Talk to your prescriber about insurance coverage and cost.

What this means for your dose schedule

Follow your prescriber's instructions, and do not adjust dose without their approval.

FAQ

What does the math on a compounded tirzepatide vial look like?

Total milligrams, total volume in mL, and concentration in mg/mL. Volume for any dose equals dose in mg divided by concentration in mg/mL.

How many doses are in a compounded tirzepatide vial?

Depends on vial size and prescribed dose. Common configurations deliver 4 to 20 doses.

How do you read the concentration off a compounded vial?

Look for "X mg/mL" on the pharmacy label. Or divide total mg by total mL if those are listed separately.

What syringe should I use to draw a compounded tirzepatide dose?

A U-100 insulin syringe. The 0.3 mL size is best for small volumes; the 0.5 or 1 mL size for larger volumes.

Why does the dose math vary between pharmacies?

Different 503A pharmacies use different concentrations (10, 20, 30, 40 mg/mL).

Is compounded tirzepatide stable in the vial across multiple doses?

Per USP 797 and pharmacy-specific stability data, typically 28-90 days from preparation. Refrigerate, inspect, and respect the beyond-use date.

Can a compounded tirzepatide vial be used with a fixed-dose pen?

No. Mounjaro and Zepbound pens are sealed devices and cannot be refilled.

What if my vial looks cloudy or discolored?

Do not use it. Contact the pharmacy. Compounded preparations should be clear and colorless.

How do I dispose of the empty vial?

Per local sharps regulations. Most U.S. states allow used vials in a sharps container along with used needles.

Can I combine doses from two vials?

Not recommended. Different vials may have different beyond-use dates, concentrations, or formulation batches. Use one vial at a time.

Is the math the same for compounded semaglutide?

The formula (volume = dose / concentration) is identical. Concentrations and prescribed doses differ between semaglutide and tirzepatide.

Related guides

• How Long Does a Vial of Tirzepatide Last? Storage, Shelf Life, and Dose-Per-Vial Math
• Compounded Semaglutide vs Compounded Tirzepatide: Vial, Dose, B12, and Cost Differences
• 33 Units on a U-100 Syringe: What Milligram Dose of Compounded GLP-1 Am I Actually Taking?
• Tirzepatide Dosage Chart: Every Dose in mg, mL, and U-100 Syringe Units
• Tirzepatide Dosing Calculator: How to Convert Any Dose to Syringe Units Accurately
• How to Reconstitute a 15 mg Tirzepatide Vial: A Step-by-Step Guide With a Full Dose Chart

Sources

1. USP 797. Pharmaceutical Compounding - Sterile Preparations. 2023 revision.
2. FDA. Compounded versions of GLP-1 medicines: safety considerations. May 2023 statement.
3. FDA. Tirzepatide drug shortages database update. 2024.
4. Eli Lilly. Mounjaro (tirzepatide) injection prescribing information. Revised 2024.
5. Eli Lilly. Zepbound (tirzepatide) injection prescribing information. Revised 2024.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
7. Frias JP et al. Tirzepatide vs Semaglutide in Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
8. ISMP. Medication Safety Alert: Errors with Compounded Tirzepatide. 2024.
9. BD Medical. U-100 Insulin Syringe technical specifications. 2023.
10. NABP. State Pharmacy Compounding Standards. 2024.
11. Endocrine Society. Clinical Practice Guideline on Pharmacologic Management of Obesity. 2015 (updated 2024).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with independently licensed clinicians and U.S. pharmacies. The math in this article is pharmacy-instructional reference, not a dose prescription. Your prescription and pharmacy label are the controlling instructions.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved. It is prepared by state-licensed 503A pharmacies in response to individual prescriptions. Vial concentrations, beyond-use dates, and excipients vary by pharmacy and must be confirmed on each refill.

Results Disclaimer. Correct dose math depends on accurate inputs from the vial label and the prescription. Errors at any step compound through the calculation. The math does not substitute for clinical judgment.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with or endorsed by Eli Lilly.